NYSE EURONEXT: LY8
REVIEW OF PERFORMANCE
Income statement
LONDON, April 30, 2020 (GLOBE NEWSWIRE) -- During the three months to 31 March 2020, the Group recorded a profit before tax of £404 million compared with a profit before tax in the three months to 31 March 2019 of £1,420 million, a decrease of £1,016 million which was largely driven by a significantly increased impairment charge due to changes to the Group's economic outlook as a result of the coronavirus pandemic.
Total income decreased by £172 million, or 4 per cent, to £3,902 million in the three months to 31 March 2020 compared with £4,074 million in the three months to 31 March 2019; there was a £166 million decrease in net interest income coupled with a small decrease of £6 million in other income.
Click on, or paste the following link into your web browser, to view the associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/5119L_1-2020-4-30.pdf (http://www.rns-pdf.londonstockexchange.com/rns/5119L_1-2020-4-30.pdf)
CONTACTS
For further information please contact:
INVESTORS AND ANALYSTS
Douglas Radcliffe
Group Investor Relations Director
020 7356 1571
douglas.radcliffe@lloydsbanking.com
Edward Sands
Director of Investor Relations
020 7356 1585
edward.sands@lloydsbanking.com
Nora Thoden
Director of Investor Relations - ESG
020 7356 2334
nora.thoden@lloydsbanking.com
CORPORATE AFFAIRS
Grant Ringshaw
Director of Media Relations
020 7356 2362
grant.ringshaw@lloydsbanking.com
Matt Smith
Head of Corporate Media
020 7356 3522
matt.smith@lloydsbanking.com
Copies of this interim management statement may be obtained from:
Investor Relations, Lloyds Banking Group plc, 25 Gresham Street, London EC2V 7HN
The statement can also be found on the Group's website - www.lloydsbankinggroup.com
Registered office: Lloyds Bank plc, 25 Gresham Street, London EC2V 7HN
Registered in England no. 2065
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/).
